Drugs / QY-1-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06251115 | Jan 2024 → Jul 2025 overdue | liver cancer | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QY-1-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06251115 ↗ |
| Modality | Cell therapy | “QY-1-T is a TCR-T drug targeting HBV-related HCC” NCT06251115 ↗ |